Benzinga | Sep 17, 2020 08:08AM EDT

Cardiff Oncology Highlights Presentation Of Data At ESMO 'Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)'

SAN DIEGO, Sept. 17, 2020 /PRNewswire/ --Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) patients at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.